Compare MITT & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MITT | VYGR |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.9M | 203.6M |
| IPO Year | N/A | 2015 |
| Metric | MITT | VYGR |
|---|---|---|
| Price | $7.68 | $3.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $9.25 | ★ $16.50 |
| AVG Volume (30 Days) | 187.6K | ★ 613.0K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 11.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | $3.48 | $34.04 |
| Revenue Next Year | $5.06 | $7.92 |
| P/E Ratio | $9.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.86 | $2.88 |
| 52 Week High | $9.27 | $5.55 |
| Indicator | MITT | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 55.96 |
| Support Level | $7.50 | $3.71 |
| Resistance Level | $7.97 | $3.82 |
| Average True Range (ATR) | 0.21 | 0.16 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 8.51 | 73.68 |
TPG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. The company focuses on its investment activities on acquiring and securitizing newly-originated residential mortgage loans within the non-agency segment of the housing market.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.